B-intervention	0	10	Conjugated
I-intervention	11	17	equine
I-intervention	18	27	oestrogen
O	28	31	and
O	32	38	breast
O	39	45	cancer
O	46	55	incidence
O	56	59	and
O	60	69	mortality
O	70	72	in
O	73	87	postmenopausal
O	88	93	women
O	94	98	with
O	99	111	hysterectomy
O	111	112	:
O	113	121	extended
O	122	128	follow
O	128	129	-
O	129	131	up
O	132	134	of
O	135	138	the
O	139	144	Women
O	144	145	'
O	145	146	s
O	147	153	Health
O	154	164	Initiative
O	165	175	randomised
O	176	183	placebo
O	183	184	-
O	184	194	controlled
O	195	200	trial
O	200	201	.

O	202	204	By
O	205	213	contrast
O	214	218	with
O	219	223	many
O	224	237	observational
O	238	245	studies
O	245	246	,
O	247	252	women
O	253	255	in
O	256	259	the
O	260	265	Women
O	265	266	'
O	266	267	s
O	268	274	Health
O	275	285	Initiative
O	286	287	(
O	287	290	WHI
O	290	291	)
O	292	297	trial
O	298	301	who
O	302	306	were
O	307	315	randomly
O	316	325	allocated
O	326	328	to
O	329	336	receive
O	337	346	oestrogen
O	347	352	alone
O	353	356	had
O	357	358	a
O	359	364	lower
O	365	374	incidence
O	375	377	of
O	378	386	invasive
O	387	393	breast
O	394	400	cancer
O	401	405	than
O	406	409	did
O	410	415	those
O	416	419	who
O	420	428	received
O	429	436	placebo
O	436	437	.

O	438	440	We
O	441	446	aimed
O	447	449	to
O	450	456	assess
O	457	460	the
O	461	470	influence
O	471	473	of
O	474	483	oestrogen
O	484	487	use
O	488	490	on
O	491	497	longer
O	498	502	term
O	503	509	breast
O	510	516	cancer
O	517	526	incidence
O	527	530	and
O	531	540	mortality
O	541	543	in
O	544	552	extended
O	553	559	follow
O	559	560	-
O	560	562	up
O	563	565	of
O	566	570	this
O	571	577	cohort
O	577	578	.

O	579	586	Between
O	587	591	1993
O	592	595	and
O	596	600	1998
O	600	601	,
O	602	605	the
O	606	609	WHI
O	610	618	enrolled
B-total-participants	619	621	10
I-total-participants	621	622	,
I-total-participants	622	625	739
B-eligibility	626	640	postmenopausal
I-eligibility	641	646	women
O	647	651	from
O	652	654	40
B-location	655	657	US
O	658	666	clinical
O	667	674	centres
O	675	679	into
O	680	681	a
O	682	692	randomised
O	692	693	,
O	694	700	double
O	700	701	-
O	701	707	masked
O	707	708	,
O	709	716	placebo
O	716	717	-
O	717	727	controlled
O	728	733	trial
O	733	734	.

O	735	740	Women
O	741	745	aged
B-age	746	748	50
I-age	748	749	-
I-age	749	751	79
I-age	752	757	years
B-eligibility	758	761	who
I-eligibility	762	765	had
I-eligibility	766	775	undergone
I-eligibility	776	788	hysterectomy
I-eligibility	789	792	and
I-eligibility	793	796	had
I-eligibility	797	805	expected
I-eligibility	806	807	3
I-eligibility	807	808	-
I-eligibility	808	812	year
I-eligibility	813	821	survival
I-eligibility	822	825	and
I-eligibility	826	837	mammography
I-eligibility	838	847	clearance
O	848	852	were
O	853	861	randomly
O	862	871	allocated
O	872	874	by
O	875	876	a
O	877	889	computerised
O	889	890	,
O	891	899	permuted
O	900	905	block
O	906	915	algorithm
O	915	916	,
O	917	927	stratified
O	928	930	by
O	931	934	age
O	935	940	group
O	941	944	and
O	945	951	centre
O	951	952	,
O	953	955	to
O	956	963	receive
O	964	968	oral
O	969	979	conjugated
O	980	986	equine
O	987	996	oestrogen
O	997	998	(
O	998	999	0
O	999	1000	·
O	1000	1003	625
O	1004	1006	mg
O	1007	1010	per
O	1011	1014	day
O	1014	1015	;
O	1016	1017	n
O	1017	1018	=
B-intervention-participants	1018	1022	5310
O	1022	1023	)
O	1024	1026	or
O	1027	1034	matched
B-control	1035	1042	placebo
O	1043	1044	(
O	1044	1045	n
O	1045	1046	=
B-control-participants	1046	1050	5429
O	1050	1051	)
O	1051	1052	.

O	1053	1056	The
O	1057	1062	trial
O	1063	1075	intervention
O	1076	1079	was
O	1080	1090	terminated
O	1091	1096	early
O	1097	1099	on
O	1100	1103	Feb
O	1104	1106	29
O	1106	1107	,
O	1108	1112	2004
O	1112	1113	,
O	1114	1121	because
O	1122	1124	of
O	1125	1127	an
O	1128	1135	adverse
O	1136	1142	effect
O	1143	1145	on
O	1146	1152	stroke
O	1152	1153	.

O	1154	1160	Follow
O	1160	1161	-
O	1161	1163	up
O	1164	1173	continued
O	1174	1179	until
O	1180	1187	planned
O	1188	1199	termination
O	1200	1201	(
O	1201	1206	March
O	1207	1209	31
O	1209	1210	,
O	1211	1215	2005
O	1215	1216	)
O	1216	1217	.

O	1218	1225	Consent
O	1226	1229	was
O	1230	1236	sought
O	1237	1240	for
O	1241	1249	extended
O	1250	1262	surveillance
O	1263	1267	from
O	1268	1271	the
O	1272	1276	9786
O	1277	1283	living
O	1284	1296	participants
O	1297	1299	in
O	1300	1306	active
O	1307	1313	follow
O	1313	1314	-
O	1314	1316	up
O	1316	1317	,
O	1318	1320	of
O	1321	1325	whom
O	1326	1330	7645
O	1331	1337	agreed
O	1337	1338	.

O	1339	1344	Using
O	1345	1349	data
O	1350	1354	from
O	1355	1359	this
O	1360	1368	extended
O	1369	1375	follow
O	1375	1376	-
O	1376	1378	up
O	1379	1380	(
O	1380	1382	to
O	1383	1386	Aug
O	1387	1389	14
O	1389	1390	,
O	1391	1395	2009
O	1395	1396	)
O	1396	1397	,
O	1398	1400	we
O	1401	1409	assessed
O	1410	1414	long
O	1414	1415	-
O	1415	1419	term
O	1420	1427	effects
O	1428	1430	of
O	1431	1440	oestrogen
O	1441	1444	use
O	1445	1447	on
O	1448	1456	invasive
O	1457	1463	breast
O	1464	1470	cancer
O	1471	1480	incidence
O	1480	1481	,
O	1482	1488	tumour
O	1489	1504	characteristics
O	1504	1505	,
O	1506	1509	and
O	1510	1519	mortality
O	1519	1520	.

O	1521	1523	We
O	1524	1528	used
O	1529	1532	Cox
O	1533	1543	regression
O	1544	1550	models
O	1551	1553	to
O	1554	1562	estimate
O	1563	1569	hazard
O	1570	1576	ratios
O	1577	1578	(
O	1578	1581	HRs
O	1581	1582	)
O	1583	1585	in
O	1586	1589	the
O	1590	1599	intention
O	1599	1600	-
O	1600	1602	to
O	1602	1603	-
O	1603	1608	treat
O	1609	1619	population
O	1619	1620	.

O	1621	1625	This
O	1626	1631	study
O	1632	1634	is
O	1635	1645	registered
O	1646	1650	with
O	1651	1665	ClinicalTrials
O	1665	1666	.
O	1666	1669	gov
O	1669	1670	,
O	1671	1677	number
O	1678	1689	NCT00000611
O	1689	1690	.

O	1691	1696	After
O	1697	1698	a
O	1699	1705	median
O	1706	1712	follow
O	1712	1713	-
O	1713	1715	up
O	1716	1718	of
O	1719	1721	11
O	1721	1722	·
O	1722	1723	8
O	1724	1729	years
O	1730	1731	(
O	1731	1734	IQR
O	1735	1736	9
O	1736	1737	·
O	1737	1738	1
O	1738	1739	-
O	1739	1741	12
O	1741	1742	·
O	1742	1743	9
O	1743	1744	)
O	1744	1745	,
O	1746	1749	the
O	1750	1753	use
O	1754	1756	of
O	1757	1766	oestrogen
O	1767	1770	for
O	1771	1772	a
O	1773	1779	median
O	1780	1782	of
O	1783	1784	5
O	1784	1785	·
O	1785	1786	9
O	1787	1792	years
O	1793	1794	(
O	1794	1795	2
O	1795	1796	·
O	1796	1797	5
O	1797	1798	-
O	1798	1799	7
O	1799	1800	·
O	1800	1801	3
O	1801	1802	)
O	1803	1806	was
O	1807	1817	associated
O	1818	1822	with
O	1823	1828	lower
B-outcome	1829	1838	incidence
I-outcome	1839	1841	of
I-outcome	1842	1850	invasive
I-outcome	1851	1857	breast
I-outcome	1858	1864	cancer
O	1865	1866	(
B-iv-bin-abs	1866	1869	151
O	1870	1875	cases
O	1875	1876	,
O	1877	1878	0
O	1878	1879	·
O	1879	1881	27
O	1881	1882	%
O	1883	1886	per
O	1887	1891	year
O	1891	1892	)
O	1893	1901	compared
O	1902	1906	with
O	1907	1914	placebo
O	1915	1916	(
B-cv-bin-abs	1916	1919	199
O	1920	1925	cases
O	1925	1926	,
O	1927	1928	0
O	1928	1929	·
O	1929	1931	35
O	1931	1932	%
O	1933	1936	per
O	1937	1941	year
O	1941	1942	;
O	1943	1945	HR
O	1946	1947	0
O	1947	1948	·
O	1948	1950	77
O	1950	1951	,
O	1952	1954	95
O	1954	1955	%
O	1956	1958	CI
O	1959	1960	0
O	1960	1961	·
O	1961	1963	62
O	1963	1964	-
O	1964	1965	0
O	1965	1966	·
O	1966	1968	95
O	1968	1969	;
O	1970	1971	p
O	1971	1972	=
O	1972	1973	0
O	1973	1974	·
O	1974	1976	02
O	1976	1977	)
O	1978	1982	with
O	1983	1985	no
O	1986	1996	difference
O	1997	1998	(
O	1998	1999	p
O	1999	2000	=
O	2000	2001	0
O	2001	2002	·
O	2002	2004	76
O	2004	2005	)
O	2006	2013	between
O	2014	2026	intervention
O	2027	2032	phase
O	2033	2034	(
O	2034	2035	0
O	2035	2036	·
O	2036	2038	79
O	2038	2039	,
O	2040	2041	0
O	2041	2042	·
O	2042	2044	61
O	2044	2045	-
O	2045	2046	1
O	2046	2047	·
O	2047	2049	02
O	2049	2050	)
O	2051	2054	and
O	2055	2059	post
O	2059	2060	-
O	2060	2072	intervention
O	2073	2078	phase
O	2079	2086	effects
O	2087	2088	(
O	2088	2089	0
O	2089	2090	·
O	2090	2092	75
O	2092	2093	,
O	2094	2095	0
O	2095	2096	·
O	2096	2098	51
O	2098	2099	-
O	2099	2100	1
O	2100	2101	·
O	2101	2103	09
O	2103	2104	)
O	2104	2105	.

O	2106	2108	In
O	2109	2117	subgroup
O	2118	2126	analyses
O	2126	2127	,
O	2128	2130	we
O	2131	2136	noted
B-outcome	2137	2143	breast
I-outcome	2144	2150	cancer
I-outcome	2151	2155	risk
I-outcome	2156	2165	reduction
O	2166	2170	with
O	2171	2180	oestrogen
O	2181	2184	use
O	2185	2188	was
O	2189	2201	concentrated
O	2202	2204	in
O	2205	2210	women
O	2211	2218	without
O	2219	2225	benign
O	2226	2232	breast
O	2233	2240	disease
O	2241	2242	(
O	2242	2243	p
O	2243	2244	=
O	2244	2245	0
O	2245	2246	·
O	2246	2248	01
O	2248	2249	)
O	2250	2252	or
O	2253	2254	a
O	2255	2261	family
O	2262	2269	history
O	2270	2272	of
O	2273	2279	breast
O	2280	2286	cancer
O	2287	2288	(
O	2288	2289	p
O	2289	2290	=
O	2290	2291	0
O	2291	2292	·
O	2292	2294	02
O	2294	2295	)
O	2295	2296	.

O	2297	2299	In
O	2300	2303	the
O	2304	2313	oestrogen
O	2314	2319	group
O	2319	2320	,
O	2321	2326	fewer
O	2327	2332	women
B-outcome	2333	2337	died
I-outcome	2338	2342	from
I-outcome	2343	2349	breast
I-outcome	2350	2356	cancer
O	2357	2358	(
B-iv-bin-abs	2358	2361	six
O	2362	2368	deaths
O	2368	2369	,
O	2370	2371	0
O	2371	2372	·
O	2372	2375	009
O	2375	2376	%
O	2377	2380	per
O	2381	2385	year
O	2385	2386	)
O	2387	2395	compared
O	2396	2400	with
O	2401	2409	controls
O	2410	2411	(
B-cv-bin-abs	2411	2413	16
O	2414	2420	deaths
O	2420	2421	,
O	2422	2423	0
O	2423	2424	·
O	2424	2427	024
O	2427	2428	%
O	2429	2432	per
O	2433	2437	year
O	2437	2438	;
O	2439	2441	HR
O	2442	2443	0
O	2443	2444	·
O	2444	2446	37
O	2446	2447	,
O	2448	2450	95
O	2450	2451	%
O	2452	2454	CI
O	2455	2456	0
O	2456	2457	·
O	2457	2459	13
O	2459	2460	-
O	2460	2461	0
O	2461	2462	·
O	2462	2464	91
O	2464	2465	;
O	2466	2467	p
O	2467	2468	=
O	2468	2469	0
O	2469	2470	·
O	2470	2472	03
O	2472	2473	)
O	2473	2474	.

O	2475	2480	Fewer
O	2481	2486	women
O	2487	2489	in
O	2490	2493	the
O	2494	2503	oestrogen
O	2504	2509	group
B-outcome	2510	2514	died
I-outcome	2515	2519	from
I-outcome	2520	2523	any
I-outcome	2524	2529	cause
I-outcome	2530	2535	after
I-outcome	2536	2537	a
I-outcome	2538	2544	breast
I-outcome	2545	2551	cancer
I-outcome	2552	2561	diagnosis
O	2562	2563	(
B-iv-bin-abs	2563	2565	30
O	2566	2572	deaths
O	2572	2573	,
O	2574	2575	0
O	2575	2576	·
O	2576	2579	046
O	2579	2580	%
O	2581	2584	per
O	2585	2589	year
O	2589	2590	)
O	2591	2595	than
O	2596	2599	did
O	2600	2608	controls
O	2609	2610	(
B-cv-bin-abs	2610	2612	50
O	2613	2619	deaths
O	2619	2620	,
O	2621	2622	0
O	2622	2623	·
O	2623	2626	076
O	2626	2627	%
O	2627	2628	;
O	2629	2631	HR
O	2632	2633	0
O	2633	2634	·
O	2634	2636	62
O	2636	2637	,
O	2638	2640	95
O	2640	2641	%
O	2642	2644	CI
O	2645	2646	0
O	2646	2647	·
O	2647	2649	39
O	2649	2650	-
O	2650	2651	0
O	2651	2652	·
O	2652	2654	97
O	2654	2655	;
O	2656	2657	p
O	2657	2658	=
O	2658	2659	0
O	2659	2660	·
O	2660	2662	04
O	2662	2663	)
O	2663	2664	.

O	2665	2668	Our
O	2669	2677	findings
O	2678	2685	provide
O	2686	2697	reassurance
O	2698	2701	for
O	2702	2707	women
O	2708	2712	with
O	2713	2725	hysterectomy
O	2726	2733	seeking
O	2734	2740	relief
O	2741	2743	of
O	2744	2755	climacteric
O	2756	2764	symptoms
O	2765	2767	in
O	2768	2773	terms
O	2774	2776	of
O	2777	2780	the
O	2781	2788	effects
O	2789	2791	of
O	2792	2801	oestrogen
O	2802	2805	use
O	2806	2809	for
O	2810	2815	about
O	2816	2817	5
O	2818	2823	years
O	2824	2826	on
O	2827	2833	breast
O	2834	2840	cancer
O	2841	2850	incidence
O	2851	2854	and
O	2855	2864	mortality
O	2864	2865	.

O	2866	2873	However
O	2873	2874	,
O	2875	2878	our
O	2879	2883	data
O	2884	2886	do
O	2887	2890	not
O	2891	2898	support
O	2899	2902	use
O	2903	2905	of
O	2906	2915	oestrogen
O	2916	2919	for
O	2920	2926	breast
O	2927	2933	cancer
O	2934	2938	risk
O	2939	2948	reduction
O	2949	2956	because
O	2957	2960	any
O	2961	2966	noted
O	2967	2974	benefit
O	2975	2983	probably
O	2984	2988	does
O	2989	2992	not
O	2993	2998	apply
O	2999	3001	to
O	3002	3013	populations
O	3014	3016	at
O	3017	3026	increased
O	3027	3031	risk
O	3032	3034	of
O	3035	3039	such
O	3040	3046	cancer
O	3046	3047	.

O	3048	3050	US
O	3051	3059	National
O	3060	3065	Heart
O	3065	3066	,
O	3067	3071	Lung
O	3071	3072	,
O	3073	3076	and
O	3077	3082	Blood
O	3083	3092	Institute
O	3092	3093	;
O	3094	3099	Wyeth
O	3099	3100	.
